BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3569 related articles for article (PubMed ID: 19059524)

  • 1. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biochemical aspects of modified, transdermal replacement hormone therapy].
    Stanosz S; Zochowska E; Stanosz M
    Ginekol Pol; 2007 Dec; 78(12):922-8. PubMed ID: 18411913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism.
    Ho KK; Weissberger AJ
    J Bone Miner Res; 1992 Jul; 7(7):821-7. PubMed ID: 1642149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects on bone mass of oral alendronate, hormone replacement therapy and combined regimes in post-menopausal women: preliminary report on a comparative study].
    Ulla MR; Araujo GL; Giglione F; Fajreldines F; Domingo P; Noriega R; Rivoira MA
    Medicina (B Aires); 1997; 57 Suppl 1():49-55. PubMed ID: 9567355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.
    O'Sullivan AJ; Crampton LJ; Freund J; Ho KK
    J Clin Invest; 1998 Sep; 102(5):1035-40. PubMed ID: 9727072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women.
    Perrone G; Falaschi P; Capri O; Pastore R; Galoppi P; D'Urso R; Martocchia A; Anelli G; Zichella L
    Int J Fertil Menopausal Stud; 1994; 39(4):202-7. PubMed ID: 7951402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
    Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
    J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
    Chiantera V; Sarti CD; Fornaro F; Farzati A; De Franciscis P; Sepe E; Borrelli AL; Colacurci N
    Menopause; 2003; 10(4):286-91. PubMed ID: 12851511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study.
    Sonnet E; Lacut K; Roudaut N; Mottier D; Kerlan V; Oger E
    Clin Endocrinol (Oxf); 2007 May; 66(5):626-31. PubMed ID: 17492948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of exercise training on bone remodeling, insulin-like growth factors, and bone mineral density in postmenopausal women with and without hormone replacement therapy.
    Milliken LA; Going SB; Houtkooper LB; Flint-Wagner HG; Figueroa A; Metcalfe LL; Blew RM; Sharp SC; Lohman TG
    Calcif Tissue Int; 2003 Apr; 72(4):478-84. PubMed ID: 12574871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
    Ichikawa J; Sumino H; Ichikawa S; Ozaki M
    Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Christiansen C
    Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
    Araújo DA; Farias ML; Andrade AT
    Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
    Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
    J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone accretion in adolescents using the combined estrogen and progestin transdermal contraceptive method Ortho Evra: a pilot study.
    Harel Z; Riggs S; Vaz R; Flanagan P; Harel D; Machan JT
    J Pediatr Adolesc Gynecol; 2010 Feb; 23(1):23-31. PubMed ID: 19647454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 179.